Durability and Outcome of Initial Antiretroviral Treatments Received during 2000–2005 by Patients in the Swiss HIV Cohort Study
Background. Little is known about time trends, predictors, and consequences of changes made to antiretroviral therapy (ART) regimens early after patients initially start treatment. Methods. We compared the incidence of, reasons for, and predictors of treatment change within 1 year after starting com...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 2008-06, Vol.197 (12), p.1685-1694 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1694 |
|---|---|
| container_issue | 12 |
| container_start_page | 1685 |
| container_title | The Journal of infectious diseases |
| container_volume | 197 |
| creator | Vo, Thi Tuyet Nhung Ledergerber, Bruno Keiser, Olivia Hirschel, Bernard Furrer, Hansjakob Battegay, Manuel Cavassini, Matthias Bernasconi, Enos Vernazza, Pietro Weber, Rainer |
| description | Background. Little is known about time trends, predictors, and consequences of changes made to antiretroviral therapy (ART) regimens early after patients initially start treatment. Methods. We compared the incidence of, reasons for, and predictors of treatment change within 1 year after starting combination ART (cART), as well as virological and immunological outcomes at 1 year, among 1866 patients from the Swiss HIV Cohort Study who initiated cART during 2000–2001, 2002–2003, or 2004–2005. Results. The durability of initial regimens did not improve over time (P = .15): 48.8% of 625 patients during 2000–2001, 43.8% of 607 during 2002–2003, and 44.3% of 634 during 2004-2005 changed cART within 1 year; reasons for change included intolerance (51.1% of all patients), patient wish (15.4%), physician decision (14.8%), and virological failure (7.1%). An increased probability of treatment change was associated with larger CD4+ cell counts, larger human immunodeficiency virus type 1 (HIV-1) RNA loads, and receipt of regimens that contained stavudine or indinavir/ritonavir, but a decreased probability was associated with receipt of regimens that contained tenofovir. Treatment discontinuation was associated with larger CD4+ cell counts, current use of injection drugs, and receipt of regimens that contained nevirapine. One-year outcomes improved between 2000–2001 and 2004–2005: 84.5% and 92.7% of patients, respectively, reached HIV-1 RNA loads of |
| doi_str_mv | 10.1086/588141 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_71619139</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>40254150</jstor_id><sourcerecordid>40254150</sourcerecordid><originalsourceid>FETCH-LOGICAL-c430t-8fff6478db819b16cfeea75f29fc9c4220f595e3e77429ed7eedf44a7b83a60f3</originalsourceid><addsrcrecordid>eNqF0ctu1DAUBmALgehQ4A1A3sAu4LvjZTtcZqRWRbQUxMZynGPqkkmK7RRmB8_AG_IkhM5oumR1dPR_Orb0I_SYkheU1OqlrGsq6B00o5LrSinK76IZIYxVtDZmDz3I-ZIQIrjS99EerSXlVMoZ-vVqTK6JXSxr7PoWn4zFDyvAQ8DLPpboOnzQl5igpOE6pmk9S-DKCvqS8XvwEK-hxe2YYv8Fs-mFPz9_T0PiZo3fuRJvXOxxuQB8-j3mjBfLczwfLoZU8GkZ2_VDdC-4LsOj7dxHH968PpsvqqOTt8v5wVHlBSelqkMISui6bWpqGqp8AHBaBmaCN14wRoI0EjhoLZiBVgO0QQinm5o7RQLfR883d6_S8G2EXOwqZg9d53oYxmw1VdRQbv4LGTGaEUluoU9DzgmCvUpx5dLaUmL_tWI3rUzw6fbi2KygvWXbGibwbAtc9q4LyfU-5p1jREzNUTG5Jxt3mcuQdrkgTAp686Nqk8dc4Mcud-mrVZpraRefPtuPii8Oz4-PreF_AXGJrPM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20972050</pqid></control><display><type>article</type><title>Durability and Outcome of Initial Antiretroviral Treatments Received during 2000–2005 by Patients in the Swiss HIV Cohort Study</title><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Vo, Thi Tuyet Nhung ; Ledergerber, Bruno ; Keiser, Olivia ; Hirschel, Bernard ; Furrer, Hansjakob ; Battegay, Manuel ; Cavassini, Matthias ; Bernasconi, Enos ; Vernazza, Pietro ; Weber, Rainer</creator><creatorcontrib>Vo, Thi Tuyet Nhung ; Ledergerber, Bruno ; Keiser, Olivia ; Hirschel, Bernard ; Furrer, Hansjakob ; Battegay, Manuel ; Cavassini, Matthias ; Bernasconi, Enos ; Vernazza, Pietro ; Weber, Rainer ; Swiss HIV Cohort Study ; Swiss HIV Cohort Study</creatorcontrib><description>Background. Little is known about time trends, predictors, and consequences of changes made to antiretroviral therapy (ART) regimens early after patients initially start treatment. Methods. We compared the incidence of, reasons for, and predictors of treatment change within 1 year after starting combination ART (cART), as well as virological and immunological outcomes at 1 year, among 1866 patients from the Swiss HIV Cohort Study who initiated cART during 2000–2001, 2002–2003, or 2004–2005. Results. The durability of initial regimens did not improve over time (P = .15): 48.8% of 625 patients during 2000–2001, 43.8% of 607 during 2002–2003, and 44.3% of 634 during 2004-2005 changed cART within 1 year; reasons for change included intolerance (51.1% of all patients), patient wish (15.4%), physician decision (14.8%), and virological failure (7.1%). An increased probability of treatment change was associated with larger CD4+ cell counts, larger human immunodeficiency virus type 1 (HIV-1) RNA loads, and receipt of regimens that contained stavudine or indinavir/ritonavir, but a decreased probability was associated with receipt of regimens that contained tenofovir. Treatment discontinuation was associated with larger CD4+ cell counts, current use of injection drugs, and receipt of regimens that contained nevirapine. One-year outcomes improved between 2000–2001 and 2004–2005: 84.5% and 92.7% of patients, respectively, reached HIV-1 RNA loads of <50 copies/mL and achieved median increases in CD4+ cell counts of 157.5 and 197.5 cells/µL, respectively (P < .001 for all comparisons). Conclusions. Virological and immunological outcomes of initial treatments improved between 2000–2001 and 2004–2005, irrespective of uniformly high rates of early changes in treatment across the 3 study intervals.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1086/588141</identifier><identifier>PMID: 18513155</identifier><identifier>CODEN: JIDIAQ</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Adult ; Anti-HIV Agents - administration & dosage ; Anti-HIV Agents - therapeutic use ; Antiretrovirals ; Biological and medical sciences ; Carts ; Cohort Studies ; Drug Administration Schedule ; Durability ; Female ; Fundamental and applied biological sciences. Psychology ; Hepatitis B - complications ; Hepatitis B virus ; Hepatitis C - complications ; HIV ; HIV 1 ; HIV Infections - complications ; HIV Infections - drug therapy ; HIV/AIDS ; Human immunodeficiency virus 1 ; Human viral diseases ; Humans ; Immunology ; Infectious diseases ; Male ; Medical sciences ; Microbiology ; Middle Aged ; RNA ; Switzerland ; Time Factors ; Treatment Outcome ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Virology</subject><ispartof>The Journal of infectious diseases, 2008-06, Vol.197 (12), p.1685-1694</ispartof><rights>Copyright 2008 Infectious Diseases Society of America</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c430t-8fff6478db819b16cfeea75f29fc9c4220f595e3e77429ed7eedf44a7b83a60f3</citedby><cites>FETCH-LOGICAL-c430t-8fff6478db819b16cfeea75f29fc9c4220f595e3e77429ed7eedf44a7b83a60f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/40254150$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/40254150$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,799,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20404314$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18513155$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vo, Thi Tuyet Nhung</creatorcontrib><creatorcontrib>Ledergerber, Bruno</creatorcontrib><creatorcontrib>Keiser, Olivia</creatorcontrib><creatorcontrib>Hirschel, Bernard</creatorcontrib><creatorcontrib>Furrer, Hansjakob</creatorcontrib><creatorcontrib>Battegay, Manuel</creatorcontrib><creatorcontrib>Cavassini, Matthias</creatorcontrib><creatorcontrib>Bernasconi, Enos</creatorcontrib><creatorcontrib>Vernazza, Pietro</creatorcontrib><creatorcontrib>Weber, Rainer</creatorcontrib><creatorcontrib>Swiss HIV Cohort Study</creatorcontrib><creatorcontrib>Swiss HIV Cohort Study</creatorcontrib><title>Durability and Outcome of Initial Antiretroviral Treatments Received during 2000–2005 by Patients in the Swiss HIV Cohort Study</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>Background. Little is known about time trends, predictors, and consequences of changes made to antiretroviral therapy (ART) regimens early after patients initially start treatment. Methods. We compared the incidence of, reasons for, and predictors of treatment change within 1 year after starting combination ART (cART), as well as virological and immunological outcomes at 1 year, among 1866 patients from the Swiss HIV Cohort Study who initiated cART during 2000–2001, 2002–2003, or 2004–2005. Results. The durability of initial regimens did not improve over time (P = .15): 48.8% of 625 patients during 2000–2001, 43.8% of 607 during 2002–2003, and 44.3% of 634 during 2004-2005 changed cART within 1 year; reasons for change included intolerance (51.1% of all patients), patient wish (15.4%), physician decision (14.8%), and virological failure (7.1%). An increased probability of treatment change was associated with larger CD4+ cell counts, larger human immunodeficiency virus type 1 (HIV-1) RNA loads, and receipt of regimens that contained stavudine or indinavir/ritonavir, but a decreased probability was associated with receipt of regimens that contained tenofovir. Treatment discontinuation was associated with larger CD4+ cell counts, current use of injection drugs, and receipt of regimens that contained nevirapine. One-year outcomes improved between 2000–2001 and 2004–2005: 84.5% and 92.7% of patients, respectively, reached HIV-1 RNA loads of <50 copies/mL and achieved median increases in CD4+ cell counts of 157.5 and 197.5 cells/µL, respectively (P < .001 for all comparisons). Conclusions. Virological and immunological outcomes of initial treatments improved between 2000–2001 and 2004–2005, irrespective of uniformly high rates of early changes in treatment across the 3 study intervals.</description><subject>Adult</subject><subject>Anti-HIV Agents - administration & dosage</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antiretrovirals</subject><subject>Biological and medical sciences</subject><subject>Carts</subject><subject>Cohort Studies</subject><subject>Drug Administration Schedule</subject><subject>Durability</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Hepatitis B - complications</subject><subject>Hepatitis B virus</subject><subject>Hepatitis C - complications</subject><subject>HIV</subject><subject>HIV 1</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>HIV/AIDS</subject><subject>Human immunodeficiency virus 1</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunology</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>RNA</subject><subject>Switzerland</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Virology</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0ctu1DAUBmALgehQ4A1A3sAu4LvjZTtcZqRWRbQUxMZynGPqkkmK7RRmB8_AG_IkhM5oumR1dPR_Orb0I_SYkheU1OqlrGsq6B00o5LrSinK76IZIYxVtDZmDz3I-ZIQIrjS99EerSXlVMoZ-vVqTK6JXSxr7PoWn4zFDyvAQ8DLPpboOnzQl5igpOE6pmk9S-DKCvqS8XvwEK-hxe2YYv8Fs-mFPz9_T0PiZo3fuRJvXOxxuQB8-j3mjBfLczwfLoZU8GkZ2_VDdC-4LsOj7dxHH968PpsvqqOTt8v5wVHlBSelqkMISui6bWpqGqp8AHBaBmaCN14wRoI0EjhoLZiBVgO0QQinm5o7RQLfR883d6_S8G2EXOwqZg9d53oYxmw1VdRQbv4LGTGaEUluoU9DzgmCvUpx5dLaUmL_tWI3rUzw6fbi2KygvWXbGibwbAtc9q4LyfU-5p1jREzNUTG5Jxt3mcuQdrkgTAp686Nqk8dc4Mcud-mrVZpraRefPtuPii8Oz4-PreF_AXGJrPM</recordid><startdate>20080615</startdate><enddate>20080615</enddate><creator>Vo, Thi Tuyet Nhung</creator><creator>Ledergerber, Bruno</creator><creator>Keiser, Olivia</creator><creator>Hirschel, Bernard</creator><creator>Furrer, Hansjakob</creator><creator>Battegay, Manuel</creator><creator>Cavassini, Matthias</creator><creator>Bernasconi, Enos</creator><creator>Vernazza, Pietro</creator><creator>Weber, Rainer</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20080615</creationdate><title>Durability and Outcome of Initial Antiretroviral Treatments Received during 2000–2005 by Patients in the Swiss HIV Cohort Study</title><author>Vo, Thi Tuyet Nhung ; Ledergerber, Bruno ; Keiser, Olivia ; Hirschel, Bernard ; Furrer, Hansjakob ; Battegay, Manuel ; Cavassini, Matthias ; Bernasconi, Enos ; Vernazza, Pietro ; Weber, Rainer</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c430t-8fff6478db819b16cfeea75f29fc9c4220f595e3e77429ed7eedf44a7b83a60f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Anti-HIV Agents - administration & dosage</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antiretrovirals</topic><topic>Biological and medical sciences</topic><topic>Carts</topic><topic>Cohort Studies</topic><topic>Drug Administration Schedule</topic><topic>Durability</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Hepatitis B - complications</topic><topic>Hepatitis B virus</topic><topic>Hepatitis C - complications</topic><topic>HIV</topic><topic>HIV 1</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>HIV/AIDS</topic><topic>Human immunodeficiency virus 1</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunology</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>RNA</topic><topic>Switzerland</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vo, Thi Tuyet Nhung</creatorcontrib><creatorcontrib>Ledergerber, Bruno</creatorcontrib><creatorcontrib>Keiser, Olivia</creatorcontrib><creatorcontrib>Hirschel, Bernard</creatorcontrib><creatorcontrib>Furrer, Hansjakob</creatorcontrib><creatorcontrib>Battegay, Manuel</creatorcontrib><creatorcontrib>Cavassini, Matthias</creatorcontrib><creatorcontrib>Bernasconi, Enos</creatorcontrib><creatorcontrib>Vernazza, Pietro</creatorcontrib><creatorcontrib>Weber, Rainer</creatorcontrib><creatorcontrib>Swiss HIV Cohort Study</creatorcontrib><creatorcontrib>Swiss HIV Cohort Study</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vo, Thi Tuyet Nhung</au><au>Ledergerber, Bruno</au><au>Keiser, Olivia</au><au>Hirschel, Bernard</au><au>Furrer, Hansjakob</au><au>Battegay, Manuel</au><au>Cavassini, Matthias</au><au>Bernasconi, Enos</au><au>Vernazza, Pietro</au><au>Weber, Rainer</au><aucorp>Swiss HIV Cohort Study</aucorp><aucorp>Swiss HIV Cohort Study</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Durability and Outcome of Initial Antiretroviral Treatments Received during 2000–2005 by Patients in the Swiss HIV Cohort Study</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>2008-06-15</date><risdate>2008</risdate><volume>197</volume><issue>12</issue><spage>1685</spage><epage>1694</epage><pages>1685-1694</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><coden>JIDIAQ</coden><abstract>Background. Little is known about time trends, predictors, and consequences of changes made to antiretroviral therapy (ART) regimens early after patients initially start treatment. Methods. We compared the incidence of, reasons for, and predictors of treatment change within 1 year after starting combination ART (cART), as well as virological and immunological outcomes at 1 year, among 1866 patients from the Swiss HIV Cohort Study who initiated cART during 2000–2001, 2002–2003, or 2004–2005. Results. The durability of initial regimens did not improve over time (P = .15): 48.8% of 625 patients during 2000–2001, 43.8% of 607 during 2002–2003, and 44.3% of 634 during 2004-2005 changed cART within 1 year; reasons for change included intolerance (51.1% of all patients), patient wish (15.4%), physician decision (14.8%), and virological failure (7.1%). An increased probability of treatment change was associated with larger CD4+ cell counts, larger human immunodeficiency virus type 1 (HIV-1) RNA loads, and receipt of regimens that contained stavudine or indinavir/ritonavir, but a decreased probability was associated with receipt of regimens that contained tenofovir. Treatment discontinuation was associated with larger CD4+ cell counts, current use of injection drugs, and receipt of regimens that contained nevirapine. One-year outcomes improved between 2000–2001 and 2004–2005: 84.5% and 92.7% of patients, respectively, reached HIV-1 RNA loads of <50 copies/mL and achieved median increases in CD4+ cell counts of 157.5 and 197.5 cells/µL, respectively (P < .001 for all comparisons). Conclusions. Virological and immunological outcomes of initial treatments improved between 2000–2001 and 2004–2005, irrespective of uniformly high rates of early changes in treatment across the 3 study intervals.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>18513155</pmid><doi>10.1086/588141</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 2008-06, Vol.197 (12), p.1685-1694 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71619139 |
| source | Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Anti-HIV Agents - administration & dosage Anti-HIV Agents - therapeutic use Antiretrovirals Biological and medical sciences Carts Cohort Studies Drug Administration Schedule Durability Female Fundamental and applied biological sciences. Psychology Hepatitis B - complications Hepatitis B virus Hepatitis C - complications HIV HIV 1 HIV Infections - complications HIV Infections - drug therapy HIV/AIDS Human immunodeficiency virus 1 Human viral diseases Humans Immunology Infectious diseases Male Medical sciences Microbiology Middle Aged RNA Switzerland Time Factors Treatment Outcome Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Virology |
| title | Durability and Outcome of Initial Antiretroviral Treatments Received during 2000–2005 by Patients in the Swiss HIV Cohort Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T09%3A17%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Durability%20and%20Outcome%20of%20Initial%20Antiretroviral%20Treatments%20Received%20during%202000%E2%80%932005%20by%20Patients%20in%20the%20Swiss%20HIV%20Cohort%20Study&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Vo,%20Thi%20Tuyet%20Nhung&rft.aucorp=Swiss%20HIV%20Cohort%20Study&rft.date=2008-06-15&rft.volume=197&rft.issue=12&rft.spage=1685&rft.epage=1694&rft.pages=1685-1694&rft.issn=0022-1899&rft.eissn=1537-6613&rft.coden=JIDIAQ&rft_id=info:doi/10.1086/588141&rft_dat=%3Cjstor_proqu%3E40254150%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20972050&rft_id=info:pmid/18513155&rft_jstor_id=40254150&rfr_iscdi=true |